KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $29.7 million.

  • Halozyme Therapeutics' Change in Receivables fell 5830.38% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.3 million, marking a year-over-year decrease of 1187.7%. This contributed to the annual value of $74.2 million for FY2024, which is 212356.99% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Change in Receivables is $29.7 million, which was down 5830.38% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Change in Receivables ranged from a high of $71.2 million in Q3 2024 and a low of -$41.1 million during Q3 2021
  • Over the past 5 years, Halozyme Therapeutics' median Change in Receivables value was $11.7 million (recorded in 2025), while the average stood at $10.1 million.
  • Data for Halozyme Therapeutics' Change in Receivables shows a peak YoY increase of 74690.28% (in 2021) and a maximum YoY decrease of 26340.76% (in 2021) over the last 5 years.
  • Over the past 5 years, Halozyme Therapeutics' Change in Receivables (Quarter) stood at -$21.1 million in 2021, then surged by 136.71% to $7.8 million in 2022, then surged by 117.73% to $16.9 million in 2023, then skyrocketed by 34.51% to $22.7 million in 2024, then soared by 30.75% to $29.7 million in 2025.
  • Its Change in Receivables was $29.7 million in Q3 2025, compared to $11.7 million in Q2 2025 and -$3.8 million in Q1 2025.